title: Potential future options in the pharmacotherapy of female sexual dysfunction.
abstract: Female sexual dysfunction (FSD) is considered a common medical problem estimated to affect millions of women in the westernized countries. FSD has been classified into four different categories including sexual arousal disorder (FSAD), sexual desire disorder (HSDD), orgasmic disorder and sexual pain disorder. The focus of this article is the potential role of pharmacological compounds currently under development, in the treatment of sexual arousal and orgasmic disorders in order to enhance the sexual response in adult females. While a number of potential therapeutic options are available to date, not one of the pharmacological treatment regimens has been yet considered the Gold standard in the management of symptoms of FSD. This article reviews the rationale and potential benefits of using distinct drug formulations in the treatment of FSD.
authors.affiliation: Department of Urology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. sue_de_99@yahoo.de
authors.forename: Stefan
authors.initials: S
authors.lastname: Uckert
authors.forename: Margit E
authors.initials: ME
authors.lastname: Mayer
authors.forename: Udo
authors.initials: U
authors.lastname: Jonas
authors.forename: Christian G
authors.initials: CG
authors.lastname: Stief
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000818:Animals; D004967:Estrogens / Q000627:therapeutic use*; D005260:Female; D020249:Hormone Replacement Therapy / Q000379:methods*; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000317:Adrenergic alpha-Antagonists; D004967:Estrogens; D010726:Phosphodiesterase Inhibitors